⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5985948 | 0.85 | — | — | |
| SCHEMBL17607562 | 0.85 | ALDH1A1 (0.30) | — | |
| SCHEMBL17607684 | 0.83 | — | — | |
| SCHEMBL8091785 | 0.83 | ALDH1A1 (0.32) | — | |
| SCHEMBL5985356 | 0.81 | — | — | |
| SCHEMBL17607425 | 0.81 | — | — | |
| SCHEMBL4653010 | 0.79 | — | — | |
| SCHEMBL17607754 | 0.79 | ALDH1A1 (0.50) | — | |
| SCHEMBL17135311 | 0.77 | ALDH1A1 (0.43) | — | |
| SCHEMBL7566789 | 0.75 | LMNA (0.46) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1353 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2006065842-A2 | 5,6,7,8-TETRAHYDROQUINOLINES AND RELATED COMPOUNDS AND USES THEREOF | SYNTA PHARMACEUTICALS CORP. (US) | 2006-06-22 | — | — | WO | claimed |
| EP-1663227-A2 | DIHYDROPYRIDINE COMPOUNDS FOR TREATING OR PREVENTING METABOLIC DISORDERS | Synta Pharmaceuticals Corporation (US) | 2006-06-07 | — | — | EP | claimed |
| US-20050203119-A1 | Dihydropyridine compounds for treating or preventing metabolic disorders | SYNTA PHARMACEUTICAL CORP. | 2005-09-15 | — | — | US | claimed |
| WO-2005025507-A2 | DIHYDROPYRIDINE COMPOUNDS FOR TREATING OR PREVENTING METABOLIC DISORDERS | SYNTA PHAMACEUTICALS CORP. (US) | 2005-03-24 | — | — | WO | claimed |
| CN-113939516-B | Methods and compositions for targeting protein degradation | 珃诺生物医药科技(杭州)有限公司 | 2024-07-16 | — | — | CN | disclosed |
| CN-115103850-B | 2-Methoxyestradiol derivatives and medical use thereof | 韩国巴斯德研究所 | 2024-07-12 | — | — | CN | disclosed |
| CN-114008028-B | Pyrimidine derivative for inhibiting growth of cancer cells and medical application thereof | 昂科比克斯有限公司 | 2024-07-09 | — | — | CN | disclosed |
| CN-114746432-B | Transition metal compound, catalyst composition comprising the same, and process for producing olefin polymer using the catalyst composition | 沙特基础工业爱思开NEXLENE私人有限公司 | 2024-06-21 | — | — | CN | disclosed |
| WO-2024128537-A1 | GALLIUM COMPOUND, COMPOSITION COMPRISING SAME FOR DEPOSITING THIN FILM, AND METHOD FOR MANUFACTURING THIN FILM USING SAME | 주식회사 레이크머티리얼즈 | 2024-06-20 | — | — | WO | disclosed |
| WO-2024128535-A1 | GALLIUM COMPOUND, COMPOSITION FOR THIN FILM DEPOSITION, COMPRISING SAME, AND THIN FILM MANUFACTURING METHOD USING SAME | 주식회사 레이크머티리얼즈 | 2024-06-20 | — | — | WO | disclosed |
| EP-4385991-A1 | COMPOUND HAVING SHP2 PROTEIN DEGRADING ACTIVITY, AND MEDICAL USES THEREOF | Ubix Therapeutics, Inc. (KR) | 2024-06-19 | — | — | EP | disclosed |
| US-12011454-B2 | Nicotinamide mononucleotide derivatives and use thereof in the treatment and prevention of a red blood cell disorder | NUVAMID SA (CH) | 2024-06-18 | — | — | US | disclosed |
| WO-2004004774-A2 | COMPOSITIONS COMPRISING PANTHETINE FOR THE TREATMENT OF DYSLIPIDEMIA | ESPERION THERAPEUTICS, INC. (US) | 2004-01-15 | — | — | WO | disclosed |
| WO-2003105774-A2 | COMPOUNDS USEFUL FOR THE TREATMENT OF CANCER, COMPOSITIONS THEREOF AND METHODS THEREWITH | SIGNAL PHARMACEUTICALS, INC. (US) | 2003-12-24 | — | — | WO | disclosed |
| WO-2003102151-A2 | MODULATING CELL DIFFERENTIATION AND TREATING MYELOPROLIFERTIVE DISORDERS WITH JNK/MKK INHIBITORS | CELGENE CORPORATION (US) | 2003-12-11 | — | — | WO | disclosed |
| WO-2003099221-A2 | METHODS FOR USING JNK INHIBITORS FOR TREATING OR PREVENTING DISEASE-RELATED WASTING | SIGNAL PHARMACEUTICALS, INC. (US) | 2003-12-04 | — | — | WO | disclosed |
| WO-2003075917-A1 | COMBINATION THERAPY FOR TREATING, PREVENTING OR MANAGING PROLIFERATIVE DISORDERS AND CANCERS | SIGNAL PHARMACEUTICALS, INC. (US) | 2003-09-18 | — | — | WO | disclosed |
| US-20030158164-A1 | Novel antiandrogenic agent | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2003-08-21 | — | — | US | disclosed |
| EP-1304334-A1 | NOVEL ANTIANDROGENIC AGENT | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2003-04-23 | — | — | EP | disclosed |
| EP-1219631-A1 | ANTIANDROGEN AGENTS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2002-07-03 | — | — | EP | disclosed |